

## Chronic Thromboembolic Pulmonary Hypertension (CTEPH) Results From an International Prospective Registry

Joanna Pepke-Zaba, MD; Marion Delcroix, MD; Irene Lang, MD; Eckhard Mayer, MD; Pavel Jansa, MD; David Ambroz, MD; Carmen Treacy, BSc; Andrea M. D'Armini, MD; Marco Morsolini, MD; Repke Snijder, MD; Paul Bresser, MD; Adam Torbicki, MD; Bent Kristensen, MD; Jerzy Lewczuk, MD; Iveta Simkova, MD; Joan A. Barberà, MD; Marc de Perrot, MD; Marius M. Hoeper, MD; Sean Gaine, MD; Rudolf Speich, MD; Miguel A. Gomez-Sanchez, MD; Gabor Kovacs, MD; Abdul Monem Hamid, MD; Xavier Jaïs, MD; G  rald Simonneau, MD

**Background**—Chronic thromboembolic pulmonary hypertension (CTEPH) is often a sequel of venous thromboembolism with fatal natural history; however, many cases can be cured by pulmonary endarterectomy. The clinical characteristics and current management of patients enrolled in an international CTEPH registry was investigated.

**Methods and Results**—The international registry included 679 newly diagnosed ( $\leq 6$  months) consecutive patients with CTEPH, from February 2007 until January 2009. Diagnosis was confirmed by right heart catheterization, ventilation-perfusion lung scintigraphy, computerized tomography, and/or pulmonary angiography. At diagnosis, a median of 14.1 months had passed since first symptoms; 427 patients (62.9%) were considered operable, 247 (36.4%) nonoperable, and 5 (0.7%) had no operability data; 386 patients (56.8%, ranging from 12.0%–60.9% across countries) underwent surgery. Operable patients did not differ from nonoperable patients relative to symptoms, New York Heart Association class, and hemodynamics. A history of acute pulmonary embolism was reported for 74.8% of patients (77.5% operable, 70.0% nonoperable). Associated conditions included thrombophilic disorder in 31.9% (37.1% operable, 23.5% nonoperable) and splenectomy in 3.4% of patients (1.9% operable, 5.7% nonoperable). At the time of CTEPH diagnosis, 37.7% of patients initiated at least 1 pulmonary arterial hypertension–targeted therapy (28.3% operable, 53.8% nonoperable). Pulmonary endarterectomy was performed with a 4.7% documented mortality rate.

**Conclusions**—Despite similarities in clinical presentation, operable and nonoperable CTEPH patients may have distinct associated medical conditions. Operability rates vary considerably across countries, and a substantial number of patients (operable and nonoperable) receive off-label pulmonary arterial hypertension–targeted treatments. (*Circulation*. 2011; 124:1973–1981.)

**Key Words:** hypertension, pulmonary ■ endarterectomy ■ chronic disease

Chronic thromboembolic pulmonary hypertension (CTEPH) most often results from obstruction of the pulmonary vascular bed by nonresolving thromboemboli. Chronic thromboembolic pulmonary hypertension can arise in patients after acute or recurrent pulmonary emboli or deep venous thrombosis.<sup>1,2</sup> Increased pulmonary vascular resis-

tance (PVR) subsequently leads to progressive pulmonary hypertension and right heart failure. In the nonoccluded areas, a pulmonary arteriopathy indistinguishable from that of pulmonary arterial hypertension (PAH) can develop and contribute to disease progression.<sup>3</sup> The incidence of CTEPH is not known, but recent studies suggest that 1% to 3.8% of

Received December 16, 2010; accepted August 23, 2011.

From the Papworth Hospital, Cambridge, United Kingdom (J.P.-Z., C.T.); University Hospital Gasthuisberg, Leuven, Belgium (M.D.); Medical University of Vienna, Vienna, Austria (I.L.); Kerckhoff Heart and Lung Center, Bad Nauheim, Germany (E.M.); Clinical Department of Cardiology and Angiology of the First Faculty of Medicine and General Teaching Hospital, Prague, Czech Republic (P.J., D.A.); San Matteo Hospital, University of Pavia, Pavia, Italy (A.M.D., M.M.); St. Antonius Ziekenhuis, Nieuwegein, the Netherlands (R.S.); Academic Medical Center, Amsterdam, the Netherlands (P.B.); Institute Tuberculosis and Lung Diseases, Warszawa, Poland (A.T.); Aarhus University Hospital, Skejby, Aarhus, Denmark (B.K.); Regional Hospital and Medical University, Wroclaw, Poland (J.L.); Slovak Medical University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia (I.S.); Hospital Cl  nic-CIBER Enfermedades Respiratorias, Universitat of Barcelona, Barcelona, Spain (J.A.B.); Toronto General Hospital, Toronto, Canada (M.d.P.); Medizinische Hochschule Hannover, Hannover, Germany (M.M.H.); Mater Misericordiae University Hospital, Dublin, Ireland (S.G.); Universit  tshospital Z  rich, Z  rich, Switzerland (R.S.); Hospital Universitario 12 Octubre, Madrid, Spain (M.A.G.-S.); Medical University of Graz, Graz, Austria (G.K.); University Paris Sud (Paris XI), INSERM U 999, H  pital Antoine B  cl  re, Clamart, France (A.M.H., X.J., G.S.).

Correspondence to Joanna Pepke-Zaba, MD, Papworth Hospital, CB3 8RE Cambridge, United Kingdom. E-mail joanna.pepkezaba@papworth.nhs.uk  
   2011 American Heart Association, Inc.

*Circulation* is available at <http://circ.ahajournals.org>

DOI: 10.1161/CIRCULATIONAHA.110.015008

patients develop the condition within 2 years of acute pulmonary embolism.<sup>4,5</sup> Without intervention, the prognosis of patients with CTEPH is poor and depends on the hemodynamic severity of pulmonary hypertension.<sup>6,7</sup>

### Clinical Perspective on p 1981

Progress in surgical and medical treatment over the past decade has considerably improved the outcome of CTEPH patients. The only potentially curative treatment is surgical removal of the obstructive material by pulmonary endarterectomy (PEA).<sup>8</sup> However, a substantial percentage of patients with CTEPH are not operable, and  $\approx 10\%$  to  $15\%$  of operated patients suffer from persistent pulmonary hypertension.<sup>9</sup> These patients may benefit from PAH-targeted therapies.<sup>10–13</sup> Previously, retrospective data have been collected from 4 European referral centers for CTEPH from Austria, Czech Republic, Germany, and Slovak Republic,<sup>14</sup> and a national CTEPH registry was established in the United Kingdom.<sup>15</sup> Here, we present short-term data from the first prospective, large-scale, international registry of patients with CTEPH including operable and nonoperable cases. We describe history and current diagnostic and treatment procedures of newly diagnosed CTEPH patients and potential associated conditions.

## Methods

### Study Design

This prospective registry was designed to include newly diagnosed ( $\leq 6$  months) consecutive patients with CTEPH who did not receive PAH-targeted treatment before diagnosis from centers in Europe and Canada between February 2007 and January 2009. The registry protocol did not interfere with the management of patients by their physician. Formal ethics approvals were obtained when required by the country's regulatory agency. The observation period was from study inclusion until death/transplantation or data analysis cut off (December 2009). Long-term follow-up is on-going.

### Inclusion Criteria

At all participating institutions, the diagnosis of CTEPH was established according to clinical guidelines valid at study initiation<sup>16</sup> and within 6 months of inclusion in the registry. To qualify for inclusion, patients had to be  $\geq 18$  years of age and pulmonary hypertension was to be confirmed by right heart catheterization<sup>16</sup> indicating a mean pulmonary artery pressure (mPAP)  $\geq 25$  mm Hg at rest or  $\geq 30$  mm Hg after exercise and a pulmonary capillary wedge pressure  $\leq 15$  mm Hg. Chronic thromboembolic pulmonary hypertension mm Hg (or  $> 15$  mm Hg if justified).

Chronic thromboembolic pulmonary hypertension was to be confirmed as the cause of pulmonary hypertension by abnormalities in ventilation/perfusion scan (at least 1 mismatched segmental perfusion defect), computed tomography (CT) scan, and/or in pulmonary angiography. Proximal lesions (webs, bands, and narrowed vessels) were identified by CT scan/pulmonary angiography. Before diagnosis, patients were required to have at least 3 months of anticoagulation therapy and no PAH-targeted treatment.

### Data Collection

Data were obtained from assessments that are routinely performed for CTEPH patients in clinical practice including medical history, clinical signs and symptoms, diagnosis, and treatment procedures.

### Surgery

The PEA procedure has been described previously.<sup>8,17</sup> Criteria for nonoperability included distal pulmonary artery obstructions,

imbalance between increased PVR and amount of accessible occlusions suggesting microvascular disease,  $PVR > 1500 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$ , age, and comorbidity. Persistent pulmonary hypertension after PEA was defined as mPAP  $> 25$  mm Hg by right heart catheterization or systolic pulmonary arterial pressure  $> 40$  mm Hg by echocardiography.

### Statistical Analysis

Data were analyzed with the SAS software package version 9.2. Results are expressed as medians with first and third quartiles (Q1–Q3) or numbers and percentages of patients with the assessment. Operable and nonoperable patients were compared using the Wilcoxon rank-sum test for continuous variables and the Fisher exact test for categorical variables. The reported *P* values are to be interpreted in the exploratory sense.


## Results

### Study Population

Between February 2007 and January 2009, 679 consecutive patients with recently diagnosed ( $\leq 6$  months) CTEPH were prospectively enrolled in 26 European centers and 1 Canadian center across 16 different countries. At the time of data cut-off, patients had been included for a minimum of 10 months; for 107 patients, follow-up in the registry was terminated because of death ( $n=62$ ), transplantation ( $n=1$ ), move to another center ( $n=35$ ), loss of follow-up ( $n=4$ ), patient's request ( $n=3$ ), and other reasons ( $n=2$ ). On the basis of the surgeon's assessment, 427 patients (63.3%) were considered operable and 247 (36.6%) nonoperable (5 patients missing data). Nonoperability was due to inaccessibility of the occlusions ( $n=118$ ), imbalance between increased PVR and amount of accessible occlusions ( $n=25$ ),  $PVR > 1500 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$  ( $n=6$ ), age ( $n=5$ ), comorbidities ( $n=33$ ), or other reason ( $n=56$ ) (4 patients missing data). The patient population was divided per treatment intention into 2 groups: operable and nonoperable. At the time of data cut-off, 386 patients (56.8%) had undergone surgery (these operated patients have been described elsewhere<sup>17</sup>); 37 operable patients had refused the procedure and did not have surgery and 7 had died before surgery (the Figure).

The characteristics of the patient population at inclusion are summarized in Table 1. The median age was 63 years, and 50.1% were men. The operable group was younger (median: 61 years) and included more men (53.4%) than the nonoperable group.

Most patients consulted first a pulmonologist (35.1%) or a cardiologist (34.4%) ( $n=678$ ). At the time of CTEPH diagnosis, a median of 14.1 months had passed since the first symptoms were observed (Q1–Q3: 7.5–32.8 months,  $n=637$ ): 14.9 months for operable and 13.1 month for nonoperable patients ( $P=0.4051$ ). The median time from last acute pulmonary embolism to CTEPH diagnosis was 12.5 months (Q1–Q3: 5.7–33.6 months,  $n=448$ ): 12.0 months for operable and 13.9 months for nonoperable patients ( $P=0.3609$ ). Most common presenting symptoms were: dyspnea (99.1%), edema (40.5%), fatigue (31.5%), chest pain (15.3%), or syncope (13.7%) ( $n=676$ ). At diagnosis, the majority of patients were in NYHA functional class III or IV. Operable patients did not differ from nonoperable patients relative to symptoms and NYHA class, although their walking distance tended to be higher, which could also be



**Figure.** Patient disposition. Operable/nonoperable patients are assessed as such at diagnosis by the PEA surgeon according to predefined criteria (see Methods). Operated patients are those patients who effectively underwent surgery. \*These patients initially deemed nonoperable were operated on.

associated with younger age (Table 1). Hematologic, biochemical and pulmonary function parameters were similar in both groups. Overall, blood group non-0 was more frequent (76.0% overall; 79.5% operable, 68.4% nonoperable patients,  $P=0.0255$ ) than observed for the general population (45%–70% in Europe and Canada).

Previous pulmonary embolism was confirmed for 74.8% of all patients, and was more frequent and recurrent in the operable group of patients (Table 2). In this group, more patients had previous massive pulmonary embolism. Previous deep vein thrombosis was observed in 56.1% of patients and was also more common in the operable group of patients (Table 2). After an acute pulmonary embolism or deep vein thrombosis event, patients received anticoagulants, including oral anticoagulants ( $n=492/519$ ), low molecular weight heparin ( $n=23$ ), unfractionated heparin ( $n=3$ ), and/or other ( $n=16$ ). Thrombolytic treatment was initiated in 14.4% of patients and a vena cava filter or clip was placed in 12.4% of patients as prevention for recurrent pulmonary embolism. Operable patients had more frequently been treated with thrombolytics possibly because of the high incidence and severity of pulmonary embolism (Table 2).

An additional cause potentially contributing to pulmonary hypertension was documented in 20.9% of patients (Table 3). This percentage was lower for the operable group (17.1%) than for the nonoperable group (27.2%). In both groups, the

most frequent associated condition was chronic obstructive pulmonary disease. The occurrence of medical conditions known previously to be associated with pulmonary embolism and CTEPH is listed in Table 4. A thrombophilic disorder and a family history of deep vein thrombosis or pulmonary embolism were more frequent in the operable group, whereas previous splenectomy, major surgery, congestive heart failure and a history of cancer were more frequent in the nonoperable group (Table 4). A history of cancer was reported for over 12% of the patients (10.1% operable and 16.6% nonoperable patients). Among 426 assessed patients, 118 (27.7%) had at least one established thrombotic risk factor including lupus anticoagulant/antiphospholipid antibodies (10.1%), protein S and C deficiency (9.6%; 8.9%), activated protein C resistance including Factor V Leiden mutation (7.7%), prothrombin gene mutation (3.5%), and antithrombin III deficiency (0.7%). At least one of these risk factors was documented in 30.5% of operable patients and in 22.3% of nonoperable patients ( $P=0.0839$ ). In addition, Factor VIII was elevated in some patients (150% < Factor VIII < 230% ( $n=19$ , 4.5%), or Factor VIII  $\geq 230\%$  ( $n=14$ , 3.3%)).

### CTEPH Diagnosis

The diagnostic evaluations are presented in Table 5. Right heart catheterization data indicated clinically significant pulmonary hypertension with elevated PVR (median: 709 dyn ·

**Table 1. Patients' Characteristics at Diagnosis**

	All Patients (n=679)	Operable Patients* (n=427)	Nonoperable Patients* (n=247)	P (Exploratory)
Gender, % male	50.1	53.4	44.5	0.0308
Ethnicity, % white	95.9	95.3	96.7	0.4277
Age, y, median [Q1;Q3]	63 [51; 72]	61 [48; 70]	67 [57; 74]	<0.0001
Weight, kg, median [Q1;Q3]	75 [65; 87]	76 [66; 88]	73 [63; 82]	0.0161
NYHA class, % I/II/III/IV	0.7/17.8/68.6/12.8	0.5/19.2/67.7/12.6	1.2/15.8/70.4/12.6	0.4922
6MWD, m, median [Q1; Q3] (n)	329 [245; 427] (589)	340 [250; 435] (373)	315 [223; 400] (214)	0.0219
Blood group non-0, % (n)	76.0 (366)	79.5 (249)	68.4 (117)	0.0255

Values are expressed as medians with first and third quartiles (Q1; Q3) or percentages; (n): patients with assessment; P values from Wilcoxon rank-sum test or Fisher exact test. NYHA indicates new York Heart Association; 6MWD, 6-minute walking distance.

\*Five patients had no data on operability.

**Table 2. Patients' History of Venous Thromboembolism**

	All Patients (n=679)	Operable Patients* (n=427)	Nonoperable Patients* (n=247)	P (Exploratory)
Confirmed previous acute PE, % (n)	74.8 (678)	77.5 (427)	70.0 (247)	0.0344
PE diagnosed more than once, % (n)	32.8 (469)	35.0 (303)	28.8 (163)	0.2145
Size of previous PE reported as massive, % (n)	40.8 (240)	47.1 (155)	29.4 (85)	0.0090
Confirmed previous DVT, % (n)	56.1 (426)	60.4 (280)	49.0 (143)	0.0295
Acute PE and DVT, % (n)	55.4 (413)	59.3 (270)	48.9 (141)	0.0477
Acute PE no DVT, % (n)	42.6 (413)	39.3 (270)	48.2 (141)	0.0926
Thrombolytic treatment, % (n)	14.4 (404)	18.5 (265)	6.6 (137)	0.0009
Vena cava filter implanted, % (n)	12.4 (491)	13.7 (322)	10.2 (166)	0.3139

P values from Fisher exact test. (n): patients with assessment. DVT indicates deep vein thrombosis; PE, pulmonary embolism.

\*5 patients had no data on operability.

$s \cdot \text{cm}^{-5}$ , mean:  $782 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$ ) and mPAP (median and mean: 47 mm Hg). In 69 patients, the pulmonary capillary wedge pressure was found to be  $>15$  mm Hg. These patients were nevertheless included in the registry as in the presence of major vessel obstructions, the assessment of wedge pressure may be difficult, or sometimes impossible.<sup>18</sup>

Ventilation-perfusion lung scintigraphy showed abnormal perfusion scans in 98.7% of patients, whereas ventilation scans were abnormal in 19.0%. Pulmonary angiography demonstrated proximal lesions of the pulmonary artery in 63.0% of patients. Similar results were observed with CT pulmonary angiography, which indicated proximal lesions of the pulmonary artery in 60.4% of patients and also dilatation of bronchial arteries in 68.4% of patients. High resolution CT

scan demonstrated mosaic perfusion pattern in 76.6% of patients. Proximal lesions and mosaic perfusion pattern were less common in the nonoperable patients.

Echocardiography revealed an enlarged right ventricle in 86.7% of patients (559/645) and abnormal right ventricular contractility in 66.7% (400/600).

### Treatment at Diagnosis

At CTEPH diagnosis, 37.9% of the patients initiated at least one PAH-targeted therapy including phosphodiesterase type V inhibitor, endothelin receptor antagonist or prostacyclin analog (Table 6). The operable group received less PAH-targeted treatments than the nonoperable group (28.3% versus 53.8%;  $P<0.0001$ ).

### Surgery

Surgical management and risk factors for in-hospital and 1-year death have been presented elsewhere in detail.<sup>17</sup> Briefly, out of 384 assessed operated patients, 189 (49.2%) had a perioperative complication; 18 (4.7%) patients died in hospital. After surgery, hemodynamics were markedly improved for patients with an assessment within 1 year after PEA: the median PVR decreased from  $736 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$  before surgery to  $248 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$  at the end of intensive care (Q1-Q3: 530–1010 and 180–398  $\text{dyn} \cdot \text{s} \cdot \text{cm}^{-5}$ , respectively,  $n=252$ ) and from  $698 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$  before surgery to  $235 \text{ dyn} \cdot \text{s} \cdot \text{cm}^{-5}$  within 1 year after surgery (Q1-Q3: 501–989 and 178–320  $\text{dyn} \cdot \text{s} \cdot \text{cm}^{-5}$ , respectively,  $n=70$ ).

### Per Country Analyses

The demography and management characteristics were collected for patients living in 16 countries, and, not surprisingly, differences were observed between individual countries. The median patient age in some countries could be as low as 55 years or as high as 68 years, and the percentage of men varied from 30.4% to 66.7%. Furthermore, the percentage of patients starting PAH-targeted treatment at diagnosis varied from 2.2% to 88.9%. The ranges for time from symptoms to diagnosis and to surgery were respectively 12 to 22 months and 12 to 116 days. A wide variation in nonoperability was observed between countries (from 12.0%–60.9%). Low-volume centers performing no or up to 10 PEAs per year (based on data from 2004–2006) reported a higher

**Table 3. Other Reported Cause for PH at Diagnosis**

	All Patients (n=679)	Operable Patients* (n=427)	Nonoperable Patients* (n=247)	P (Exploratory)
Other reported cause for PH, % (n)†	20.9 (675)	17.1 (427)	27.2 (246)	0.0022
COPD, %	9.5	8.4	11.0	0.2753
Sleep disorder breathing, %	3.1	2.1	4.9	0.0636
Left ventricular diastolic dysfunction, %	1.9	0.9	3.7	0.0188
Left-sided valvular heart disease, %	1.6	0.5	3.7	0.0027
Interstitial lung disease, %	1.3	0.7	2.4	0.0806
Drugs/toxins, %	1.5	1.2	2.0	0.5097

P values from the Fisher exact test. (n): patients with assessment. PH indicates pulmonary hypertension; COPD, chronic obstructive pulmonary disease.

\*Five patients had no data on operability.

†Cause for PH is reported if occurrence is  $>1.5\%$  in any patient group.



**Table 4. Associated Medical Conditions at Diagnosis**

	All Patients (n=679)	Operable Patients* (n=427)	Nonoperable Patients* (n=247)	P (Exploratory)
Associated conditions, % (n)	78.4 (677)	77.0 (426)	80.6 (247)	0.2878
Thrombophilic disorder, %	31.9	37.1	23.5	0.0003
Previous major surgery, %	21.7	18.8	26.7	0.0197
Varicose veins, %	20.8	20.4	21.1	0.8440
Obesity, %	17.6	16.7	19.0	0.4623
Chronic venous insufficiency, %	15.5	16.0	14.6	0.6596
Prolonged hospitalization, %	16.0	16.0	15.8	1.0000
History of cancer, %	12.7	10.1	16.6	0.0156
Coronary disease and/or myocardial infarction, %	11.8	11.0	13.4	0.3883
Thyroid disorder and hormone replacement therapy, %	8.4	7.7	9.3	0.4732
Family history of DVT or PE, %	6.6	8.2	4.0	0.0382
Fracture, %	5.5	5.9	4.5	0.4815
Non-insulin-dependent diabetes mellitus, %	5.2	5.4	4.9	0.8580
Congestive heart failure, %	4.6	2.8	7.7	0.0065
Splenectomy, %	3.4	1.9	5.7	0.0118
Ventriculoatrial shunt, %	0.9	0.7	1.2	0.6743
Inflammatory bowel disease, %	0.7	1.2	0	0.1641
Infection of ventriculoatrial shunt or pacemaker, %	0	0	0	...

P values from Fisher exact test. (n): patients with assessment. DVT indicates deep vein thrombosis; PE, pulmonary embolism.

\*Five patients had no data on operability.

percentage of nonoperable patients (47.1% out of n=172) than intermediate centers performing 11 to 50 PEAs per year (31.5%, n=295) or high-volume centers performing >50 PEAs per year (34.4%, n=212) ( $P=0.0008$ ), suggesting that center expertise may have influenced the decision to operate. However, further investigation would be necessary to ascertain the reasons for the variability observed in operability

rates because a referral bias may also have affected the largest surgical centers.

### Death/Transplantation

At the end of the observation period, 1 patient was documented as transplanted and 62 as dead. Most frequent causes for death were perioperative complications (n=18) and right

**Table 5. Diagnosis Evaluations**

	All Patients (n=679)	Operable Patients* (n=427)	Nonoperable Patients* (n=247)	P (Exploratory)
Right heart catheterization				
mPAP†, mm Hg, median [Q1; Q3] (n)	47 [38; 55] (669)	47 [38; 55] (423)	47 [38; 55] (244)	0.5064
PVR‡, dyn · s · cm <sup>-5</sup> , median [Q1; Q3] (n)	709 [480; 988] (604)	717 [495; 963] (381)	691 [426; 1051] (221)	0.7408
Cardiac index, L · min <sup>-1</sup> · m <sup>-2</sup> median [Q1;Q3] (n)	2.2 [1.8; 2.7] (632)	2.2 [1.8; 2.7] (404)	2.3 [1.8; 2.8] (227)	0.1343
Scintigraphy, % (n)				
Perfusion scan abnormal	98.7 (535)	99.4 (344)	97.4 (189)	0.1031
Ventilation scan abnormal	19.0 (484)	17.5 (314)	22.0 (168)	0.2736
Angiography, % (n)				
Proximal lesions	63.0 (552)	70.9 (358)	48.2 (191)	<0.0001
CT scan, % (n)				
Proximal lesions	60.4 (541)	70.1 (345)	43.0 (193)	<0.0001
Dilation of bronchial arteries	68.4 (345)	75.0 (216)	57.0 (128)	0.0008
Mosaic perfusion pattern	76.6 (414)	82.4 (261)	67.1 (152)	0.0007

P values from Wilcoxon rank-sum test or Fisher exact test. (n): patients with assessment. CT indicates computed tomography; mPAP, mean pulmonary arterial pressure; and PVR, pulmonary vascular resistance.

\*Five patients had no data on operability.

†mPAP: 12 values <25 mm Hg; 4 values >75 mm Hg.

‡PVR: 13 values <200 dyn · s · cm<sup>-5</sup>.

**Table 6. PAH-Targeted Therapy Initiated at Diagnosis**

	All Patients (n=679)	Operable Patients* (n=427)	Nonoperable Patients* (n=247)	P (Exploratory)
PAH-targeted therapy, % (n)	37.9 (676)	28.3 (427)	53.8 (247)	<0.0001
Phosphodiesterase type V inhibitor, %	17.5	16.2	19.4	0.2923
Endothelin receptor antagonist, %	21.7	12.2	37.7	<0.0001
Prostacyclin analogue, %	2.7	1.6	4.5	0.0443
Combination therapies, %	4.0	1.6	7.7	0.0002

P values from Fisher exact test. (n): patients with assessment. PAH indicates pulmonary arterial hypertension.

\*Five patients had no data on operability.

heart failure (n=17). Comparison between the operable and nonoperable patient groups will be performed once 3-year follow-up data are available.

## Discussion

With 679 patients included from Europe and Canada, the present prospective registry represents the largest contemporary population of patients with CTEPH, including newly diagnosed operable and nonoperable cases. The aim of the current report is to describe the disease at presentation along with short-term outcome; long-term follow-up is currently ongoing. The main findings are differences in occurrence of associated medical conditions between operable and nonoperable patients despite similarities in disease presentation, suggesting that these patients represent 2 distinct subpopulations.

Although PEA is the acknowledged treatment of choice for CTEPH, between 10% and 50% of referred patients may not be eligible for this procedure.<sup>19</sup> In the current registry, 36.6% of the evaluated patients (n=674) were assessed as nonoperable, with a large variation between countries (from 12.0% to 60.9%). Criteria for surgical suitability have been described,<sup>20</sup> but remain expertise dependent and ill-defined as there is currently no consensus among experts about the definition of proximal CTEPH, potentially curable with surgery, and distal CTEPH, presumably associated with small vessel arteriopathy and poor surgical outcome.<sup>21</sup>

The registry results support the thromboembolic cause of CTEPH, with 74.8% of patients presenting with previous acute pulmonary embolism and 56.1% with previous deep vein thrombosis. This is in agreement with recent studies,<sup>14,18</sup> but contrasts with previous retrospective reports indicating no history of venous thromboembolism in 40% to 60% of the patients.<sup>22–24</sup> Increased awareness of thromboembolism in the participating registry centers may have contributed to higher detection. As previously documented,<sup>18</sup> a history of acute pulmonary embolism was less common in patients with a nonoperable disease. These patients also had less massive pulmonary embolism, which is in line with a more distal disease and a possible process of in situ thrombosis.<sup>25</sup> In this registry, 12.4% of patients received a vena cava filter as a treatment for recurrent acute pulmonary embolism and, as previously reported,<sup>17</sup> only 40.2% of operable patients had a vena cava filter inserted, whereas this preoperative procedure has been systematically applied in other patient series.<sup>8,26</sup>

Although CTEPH patients are a heterogeneous group with respect to hemodynamic status and surgical accessibility of pulmonary thromboemboli resulting in operability or nonop-

erability, they presented also with many similarities at diagnosis, suggesting an underlying common disease process. In line with previous reports,<sup>8,14,15</sup> CTEPH was almost equally frequent in men and women in their sixth decade of life. Operable patients were younger than nonoperable patients but presented with similar disease severity as assessed by New York Heart Association (NYHA) functional class. This is consistent with findings from Bonderman et al,<sup>27</sup> in a retrospective analysis of 181 European CTEPH patients, and from Condliffe et al<sup>15</sup> in a retrospective study of 469 CTEPH patients from the United Kingdom. An increased awareness of pulmonary embolism and of CTEPH as a subsequent complication may be responsible for reduced time to diagnosis in both operable and nonoperable patients after the last acute pulmonary embolism event (12.5 months) and the symptom onset (14.1 months) compared with past studies reporting a diagnostic delay of several years.<sup>28,29</sup> The symptoms preceding the diagnosis of CTEPH have been described previously,<sup>1</sup> and did not differ in the present study. Effective imaging technologies including conventional and CT pulmonary angiography were widely used to examine large-vessel occlusion, revealing a higher occurrence of proximal lesions in the group of patients that was operable.

Chronic thromboembolic pulmonary hypertension patients are characterized by numerous severe comorbidities.<sup>14,18,30</sup> In particular, chronic obstructive pulmonary disease was observed in as many as 9.5% of the patients. A history of splenectomy was more frequent in the CTEPH registry patients than reported in patients with other chronic pulmonary conditions,<sup>30</sup> and was frequently associated with nonoperability (ie, with a distal type of CTEPH or a significant comorbidity). This is in line with the postulated link between abnormal postsplenectomy erythrocyte activities or abnormal platelet activation and the development of a primarily distal CTEPH disease.<sup>14,30</sup> A history of cancer was reported in this registry for >12% of the patients, which supports the concept that malignancy and/or treatment for malignancy could be a risk factor for CTEPH.<sup>14</sup> A thrombophilic disorder was present in nearly one third of the patients, and as reported previously, CTEPH patients were more likely to have a blood group other than O<sup>14</sup>; these observations were even more pronounced in the operable group. A number of inherited and acquired coagulation abnormalities have been identified in recent years that may contribute to the development of CTEPH. These include lupus anticoagulant and antiphospholipid antibodies; deficiencies of protein C, protein S, and antithrombin III; presence of factor V Leiden, and prothrom-

bin gene mutations.<sup>23,31,32</sup> These abnormalities were identified in 27.7% of the registry patients and tended overall to be more frequent in operable patients in line with more impaired thromboemboli resolution. The current results confirm that antiphospholipid antibodies, along with lupus anticoagulant, 2 thrombophilic factors associated with recurrent thrombosis,<sup>33,34</sup> are elevated in patients with CTEPH. However, a prothrombotic pathogenic mechanism involving Factor VIII in the development of CTEPH was not corroborated.<sup>35</sup> A detailed investigation of the risk factors involved in CTEPH will be the subject of a separate publication.

This registry emphasizes the seriousness of the disease, with 62 patients out of 679 documented as having died during the observation period of the study ( $\geq 10$  months). It also reflects the changes that have occurred in the management of CTEPH over recent years, including the increasing success rate of PEA surgery and the availability of PAH-targeted therapies. The low in-hospital mortality rate of 4.7% after surgery reported here is in line with continuously improving surgical results in recent worldwide series.<sup>8,15,27,36</sup> Although surgical intervention with PEA is the preferred treatment in eligible patients, CTEPH patients may benefit from the pharmacotherapy that has been developed for PAH.<sup>10,13</sup> Despite the absence of robust data from randomized, controlled trials, the prescription of these medications, even in operable CTEPH, has increased over the past years.<sup>15,37</sup> Jensen et al<sup>37</sup> reported an increase in patients treated with PAH-targeted therapies before PEA from 19.9% in 2005 to 37% in 2007. This change in prescribing practice is confirmed by the present registry, with 28.3% of the operable patients and 53.8% of the nonoperable patients initiating at least 1 PAH-targeted therapy at diagnosis. Because of unequal medical resources and/or possibly different medical practices, these percentages can be highly country dependent. Cautious use of PAH-targeted therapies is, however, endorsed by current guidelines<sup>38</sup>: Preoperative treatment has been reported to have minimal effect on pre-PEA hemodynamics and no effect on post-PEA outcome,<sup>37</sup> and may induce unnecessary delay to a potentially curative surgical intervention.<sup>17</sup>

The limitations of the study are inherent to a registry design: Some assessments were not systematically collected, leading to underreporting (eg, blood groups and thrombotic risk factors). Given that most of the participating centers were referral centers for CTEPH and PEA, the proportion of operable patients may have been overestimated because of referral bias. Per country analyses have to be interpreted cautiously, because the number of patients in some countries could be small and not representative. Finally, no patient was excluded from the analysis even when not satisfying the inclusion criteria; as a consequence, 10 patients had no right heart catheterization.

## Conclusions

The similarities between operable and nonoperable CTEPH patients necessitate a very careful diagnostic process with high-quality angiography and right heart catheterization hemodynamic evaluation to assess operability. Nevertheless, operable and nonoperable CTEPH patients may differ relative to the occurrence of associated medical conditions: In partic-

ular, thrombophilic disorders tend to be more frequent in operable patients, whereas splenectomy and cancer are more common in nonoperable patients. The registry data highlight the importance of previous venous thromboembolism events as a causal factor for the development of CTEPH, along with a significant role for associated medical risk factors as coexisting mechanisms in the disease process. A substantial number of patients (operable and nonoperable) are currently being treated with off-label treatments. The registry data also indicate that, whereas PEA can be performed with a low in-hospital mortality rate, operability rates may vary considerably across centers and countries. The indication for PEA is not clearly defined, and is dependent on the experience of the surgical team. With surgical progress constantly extending the selection of patients who can benefit from surgery, a consensus among experts is needed to reassess the criteria for operability. The ongoing 3-year follow-up of this large patient cohort will make it possible to evaluate the impact of the contemporary management of CTEPH on patient survival compared with published series.

## Acknowledgments

The authors acknowledge the contribution of the following investigators: J. Behr, Klinikum der Universität München-Grosshadern, München, Germany; R. Ewert, Ernst Moritz Arndt Universität, Greifswald, Germany; M. Confalonieri, University Hospital of Cattinara-Trieste, Trieste, Italy; D. Vizza, Policlinico Universitario Umberto I, Roma, Italy; and A. Boonstra, Vrije Universiteit Medisch Centrum, Amsterdam, the Netherlands. The authors also thank Sylvie I. Ertel (Sundgau Medical Writers, France) for editorial assistance, Jürgen Müller and Werner Baurecht (Acromion GmbH, Germany) for statistical analyses, and Rita Locher (Association for Research in CTEPH, Switzerland) for project management. The CTEPH Registry is owned and managed by the Association for Research in CTEPH. The association is headed by an executive board, composed of CTEPH experts. The executive board of the association was responsible for the design of the registry, provided input into the analyses, decided on medical interpretation, and drove the publication.

## Sources of Funding

The CTEPH registry is supported by a research grant from Actelion Pharmaceuticals Ltd. Actelion did not participate in registry management or in data analyses.

## Disclosures

Dr Pepke-Zaba has received honoraria for lecturing from Bayer, Actelion, Pfizer, and GSK, and is on advisory boards for Actelion, Pfizer, Bayer, GSK, United Therapeutics, and Eli Lilly. Dr Delcroix has received grants from Actelion, GSK, Bayer, United Therapeutics, and Pfizer, speaker fees from Actelion, Pfizer, and United Therapeutics, and consultant/steering committee member fees from Actelion, United Therapeutics, GSK, and Pfizer. Dr Lang has received grants from Actelion, research support from AOP Orphan, fees for lecturing and honoraria from Actelion, Bayer, GSK, Pfizer, and United Therapeutics, and is on advisory boards for Actelion, Bayer, GSK, Pfizer, and United Therapeutics. Dr Mayer has received speaker fees from Actelion, Bayer, and Pfizer, and consultant fees from Bayer. Dr Jansa has received grants for serving as investigator in an investigator-initiated trial (Treprostinil in CTEPH) and speaker and investigator fees from Bayer. Dr Ambroz received grants for serving as investigator in an investigator-initiated trial (Treprostinil in CTEPH) and investigator fees from Bayer. Dr Snijder has received research support from Actelion, has received honoraria from Actelion and Bayer, and is on advisory boards for Actelion, GSK, and Pfizer. Dr Bresser has received grants from Actelion. Dr Torbicki has

received speaker fees from Actelion, Bayer, United Therapeutics, Eli Lilly, and GSK and consultant fees from Actelion, Eli Lilly, GSK, Bayer, and mondoBIOTECH. Dr de Perrot, Dr Kovacs, and Dr Hamid have received honoraria from Actelion. Dr Hoeper has received honoraria and consultant fees from Actelion, Bayer, Gilead, GSK, Eli Lilly, Novartis, and Pfizer. Dr Gaine has received speaker fees and honoraria and is on advisory boards for Actelion, GSK, and Pfizer. Dr Speich has received grants from Actelion and Bayer. Dr Gomez-Sanchez has received fees for serving as investigator, consultant, or steering committee member from Actelion, Eli Lilly, GSK, and Pfizer. Drs Kovacs and Hamid have received honoraria from Actelion. Dr Jais has received honoraria from Actelion, GSK, Pfizer, and Eli Lilly. Dr Simonneau has received grants from Actelion, GSK, Eli Lilly, and Pfizer, lecture fees and honoraria from Actelion, GSK, and Pfizer, and consultant fees from Actelion, Pfizer, and Bayer. The other authors report no conflicts.

## References

- Moser KM, Auger WR, Fedullo PF. Chronic major-vessel thromboembolic pulmonary hypertension. *Circulation*. 1990;81:1735–1743.
- Auger WR, Kim NH, Kerr KM, Test VJ, Fedullo PF. Chronic thromboembolic pulmonary hypertension. *Clin Chest Med*. 2007;28:255–269.
- Hoeper MM, Mayer E, Simonneau G, Rubin LJ. Chronic thromboembolic pulmonary hypertension. *Circulation*. 2006;113:2011–2020.
- Becattini C, Agnelli G, Pesavento R, Silingardi M, Poggio R, Taliani MR, Ageno W. Incidence of chronic thromboembolic pulmonary hypertension after a first episode of pulmonary embolism. *Chest*. 2006;130:172–175.
- Pengo V, Lensing AW, Prins MH, Marchiori A, Davidson BL, Tiozzo F, Albanese P, Biasiolo A, Pegoraro C, Illiceto S, Prandoni P. Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. *N Engl J Med*. 2004;350:2257–2264.
- Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism: late prognosis and evolution of hemodynamic and respiratory data. *Chest*. 1982;81:151–158.
- Lewczuk J, Piszko P, Jagas J, Porada A, Wojciak S, Sobkowicz B, Wrabec K. Prognostic factors in medically treated patients with chronic pulmonary embolism. *Chest*. 2001;119:818–823.
- Jamieson SW, Kapelanski DP, Sakakibara N, Manecke GR, Thistlethwaite PA, Kerr KM, Channick RN, Fedullo PF, Auger WR. Pulmonary endarterectomy: experience and lessons learned in 1,500 cases. *Ann Thorac Surg*. 2003;76:1457–1462.
- Auger WR, Fedullo PF. Chronic thromboembolic pulmonary hypertension. *Semin Respir Crit Care Med*. 2009;30:471–483.
- Bresser P, Fedullo PF, Auger WR, Channick RN, Robbins IM, Kerr KM, Jamieson SW, Rubin LJ. Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2004;23:595–600.
- Suntharalingam J, Treacy CM, Doughty NJ, Goldsmith K, Soon E, Toshner MR, Sheares KK, Hughes R, Morrell NW, Pepke-Zaba J. Long-term use of sildenafil in inoperable chronic thromboembolic pulmonary hypertension. *Chest*. 2008;134:229–236.
- Hughes RJ, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I, Simonneau G, Pepke-Zaba J. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. *Eur Respir J*. 2006;28:138–143.
- Jais X, D'Armini AM, Jansa P, Torbicki A, Delcroix M, Ghofrani HA, Hoeper MM, Lang IM, Mayer E, Pepke-Zaba J, Perchenet L, Morganti A, Simonneau G, Rubin LJ. Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFIT (Bosentan Effects in iNoperable Forms of chronic Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. *J Am Coll Cardiol*. 2008;52:2127–2134.
- Bonderman D, Wilkens H, Wakounig S, Schafers HJ, Jansa P, Lindner J, Simkova I, Martischke AM, Dudeczak J, Sadushi R, Skoro-Sajer N, Klepetko W, Lang IM. Risk factors for chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2009;33:325–331.
- Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Hodgkins D, Goldsmith K, Hughes RJ, Sheares K, Tsui SS, Armstrong JJ, Torpy C, Crackett R, Carlin CM, Das C, Coghlan JG, Pepke-Zaba J. Improved outcomes in medically and surgically treated chronic thromboembolic pulmonary hypertension. *Am J Respir Crit Care Med*. 2008;177:1122–1127.
- Galie N, Torbicki A, Barst R, Darteville P, Haworth S, Higenbottam T, Olschewski H, Peacock A, Pietra G, Rubin LJ, Simonneau G, Priori SG, Garcia MA, Blanc JJ, Budaj A, Cowie M, Dean V, Deckers J, Burgos EF, Lekakis J, Lindahl B, Mazzotta G, McGregor K, Morais J, Oto A, Smiseth OA, Barbera JA, Gibbs S, Hoeper M, Humbert M, Naeije R, Pepke-Zaba J. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. *Eur Heart J*. 2004;25:2243–2278.
- Mayer E, Jenkins D, Lindner J, D'Armini A, Klock J, Meyns B, Ilkjaer LB, Klepetko W, Delcroix M, Lang I, Pepke-Zaba J, Simonneau G, Darteville P. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. *J Thorac Cardiovasc Surg*. 2011;141:702–710.
- Condliffe R, Kiely DG, Gibbs JS, Corris PA, Peacock AJ, Jenkins DP, Goldsmith K, Coghlan JG, Pepke-Zaba J. Prognostic and aetiological factors in chronic thromboembolic pulmonary hypertension. *Eur Respir J*. 2009;33:332–338.
- Peacock A, Simonneau G, Rubin L. Controversies, uncertainties and future research on the treatment of chronic thromboembolic pulmonary hypertension. *Proc Am Thorac Soc*. 2006;3:608–614.
- Kim NH. Assessment of operability in chronic thromboembolic pulmonary hypertension. *Proc Am Thorac Soc*. 2006;3:584–588.
- Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R. Updated clinical classification of pulmonary hypertension. *J Am Coll Cardiol*. 2009;54:S43–S54.
- Wolf M, Boyer-Neumann C, Parent F, Eschwege V, Jaillat H, Meyer D, Simonneau G. Thrombotic risk factors in pulmonary hypertension. *Eur Respir J*. 2000;15:395–399.
- Bonderman D, Jakowitsch J, Adlbrecht C, Schemper M, Kyrle PA, Schonauer V, Exner M, Klepetko W, Kneussl MP, Maurer G, Lang I. Medical conditions increasing the risk of chronic thromboembolic pulmonary hypertension. *Thromb Haemost*. 2005;93:512–516.
- Lang IM. Chronic thromboembolic pulmonary hypertension: not so rare after all. *N Engl J Med*. 2004;350:2236–2238.
- Egermayer P, Peacock AJ. Is pulmonary embolism a common cause of chronic pulmonary hypertension? Limitations of the embolic hypothesis. *Eur Respir J*. 2000;15:440–448.
- Thistlethwaite PA, Kaneko K, Madani MM, Jamieson SW. Technique and outcomes of pulmonary endarterectomy surgery. *Ann Thorac Cardiovasc Surg*. 2008;14:274–282.
- Bonderman D, Skoro-Sajer N, Jakowitsch J, Adlbrecht C, Dunkler D, Taghavi S, Klepetko W, Kneussl M, Lang IM. Predictors of outcome in chronic thromboembolic pulmonary hypertension. *Circulation*. 2007;115:2153–2158.
- Simonneau G, Azarian R, Brenot F, Darteville PG, Musset D, Duroux P. Surgical management of unresolved pulmonary embolism: a personal series of 72 patients. *Chest*. 1995;107:52S–55S.
- Fedullo PF, Auger WR, Channick RN, Moser KM, Jamieson SW. Chronic thromboembolic pulmonary hypertension. *Clin Chest Med*. 1995;16:353–374.
- Jais X, Ios V, Jardim C, Sitbon O, Parent F, Hamid A, Fadel E, Darteville P, Simonneau G, Humbert M. Splenectomy and chronic thromboembolic pulmonary hypertension. *Thorax*. 2005;60:1031–1034.
- Blauwet LA, Edwards WD, Tazelaar HD, McGregor CG. Surgical pathology of pulmonary thromboendarterectomy: a study of 54 cases from 1990 to 2001. *Hum Pathol*. 2003;34:1290–1298.
- Bernard J, Yi ES. Pulmonary thromboendarterectomy: a clinicopathologic study of 200 consecutive pulmonary thromboendarterectomy cases in one institution. *Hum Pathol*. 2007;38:871–877.
- Horbach DA, van Oort E, Donders RC, Derksen RH, de Groot PG. Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus: comparison between different assays for the detection of antiphospholipid antibodies. *Thromb Haemost*. 1996;76:916–924.
- Greaves M. Antiphospholipid antibodies and thrombosis. *Lancet*. 1999;353:1348–1353.
- Bonderman D, Turecek PL, Jakowitsch J, Weltermann A, Adlbrecht C, Schneider B, Kneussl M, Rubin LJ, Kyrle PA, Klepetko W, Maurer G, Lang IM. High prevalence of elevated clotting factor VIII in chronic thromboembolic pulmonary hypertension. *Thromb Haemost*. 2003;90:372–376.
- Matsuda H, Ogino H, Minatoya K, Sasaki H, Nakanishi N, Kyotani S, Kobayashi J, Yagihara T, Kitamura S. Long-term recovery of exercise ability after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension. *Ann Thorac Surg*. 2006;82:1338–1343.



37. Jensen KW, Kerr KM, Fedullo PF, Kim NH, Test VJ, Ben-Yehuda O, Auger WR. Pulmonary hypertensive medical therapy in chronic thromboembolic pulmonary hypertension before pulmonary thromboendarterectomy. *Circulation*. 2009;120:1248–1254.
38. McLaughlin VV, Archer SL, Badesch DB, Barst RJ, Farber HW, Lindner JR, Mathier MA, McGoon MD, Park MH, Rosenson RS, Rubin LJ, Tapson VF, Varga J, Harrington RA, Anderson JL, Bates ER, Bridges CR, Eisenberg MJ, Ferrari VA, Grines CL, Hlatky MA, Jacobs AK, Kaul S, Lichtenberg RC, Moliterno DJ, Mukherjee D, Pohost GM, Schofield RS, Shubrooks SJ, Stein JH, Tracy CM, Weitz HH, Wesley DJ. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc, and the Pulmonary Hypertension Association. *Circulation*. 2009;119:2250–2294.

### CLINICAL PERSPECTIVE

We present short-term data from a large, prospective, international (mostly European) noninterventional registry of newly diagnosed patients with chronic thromboembolic pulmonary hypertension, including operable and nonoperable cases. In this registry, the diagnosis of chronic thromboembolic pulmonary hypertension was often delayed, with a median of 14 months after the initial symptoms. Three quarters of patients had a history of prior acute pulmonary embolism. One third of patients received pulmonary endarterectomy with a mortality rate of 4.7%. Although clinical symptoms, New York Heart Association class, and hemodynamics were not different between operable and nonoperable patients, nonoperable patients were older, had a lower 6-minute walk test, had smaller pulmonary emboli in the past, were less likely to receive thrombolytic therapy with their prior pulmonary embolus, and were more likely to have other causes of pulmonary hypertension. The large difference in rates of pulmonary endarterectomy between countries suggests other local factors influenced the decision to operate on patients with chronic thromboembolic pulmonary hypertension. The indication for pulmonary endarterectomy is not clearly defined, and is dependent on the experience of the surgical team. About one third of patients (operable and nonoperable) received off-label pulmonary hypertension–targeted treatments. Finally, these data emphasize the deadly nature of the disease, with death documented for 62 patients out of 679 during the observation period of the study ( $\geq 10$  months).